M-14011 Carbohydrate Antigen 19-9 (CA19-9) Quantitative Test Kit

Clinical Significance:
In patients with liver cancer, serum CA19-9 levels are often significantly elevated. CA19-9 levels correlate positively with clinical stage, tumor size, and lymph node metastasis. After surgical treatment, CA19-9 levels decrease significantly but rise again upon recurrence. Monitoring changes in CA19-9 levels over time has clinical significance for tracking the disease progression, evaluating treatment efficacy, and predicting prognosis in liver cancer patients.
Elevated serum CA19-9 levels can also be observed in other malignancies such as pancreatic cancer, gastric cancer, lung cancer, colorectal cancer, and ovarian cancer. Serum CA242 detection assists in monitoring the disease progression, evaluating treatment efficacy, and predicting prognosis for these tumors.
Non-neoplastic diseases such as chronic pancreatitis, cholelithiasis, liver cirrhosis, renal insufficiency, and diabetes may also present with elevated CA19-9 levels, though typically at low concentrations or transiently. Serum CA19-9 testing aids in the differential diagnosis of benign and malignant gastrointestinal diseases (e.g., pancreatic cancer vs. pancreatitis, gastric cancer vs. gastric ulcer).
Product Specifications: 20 tests per box
Product Shelf Life: Sealed in an aluminum foil bag, the product is valid for 18 months. Once opened, the aluminum foil bag should be used within 1 hour.
Product Storage: Store the test cards at 2°C to 30°C.
 
Usage Scenarios:
Hospitals and Oncology Departments: For monitoring liver cancer progression, evaluating treatment efficacy, and predicting prognosis by tracking CA19-9 levels.
Gastroenterology Clinics: For differentiating between benign and malignant gastrointestinal diseases, such as pancreatic cancer vs. pancreatitis and gastric cancer vs. gastric ulcer.
Diagnostic Laboratories: For routine testing of serum CA19-9 levels to aid in the diagnosis and management of various malignancies, including pancreatic, gastric, lung, colorectal, and ovarian cancers.
Cancer Screening Programs: For regular screening and monitoring of high-risk populations for early detection of malignancies associated with elevated CA19-9 levels.
Suitable Countries and Regions:
Developed Countries: United States, Canada, Western Europe (e.g., Germany, France, UK), Japan, Australia, etc., where advanced diagnostic tools are widely used for comprehensive cancer management and early detection.
Emerging Markets: China, India, Southeast Asia, Latin America, Eastern Europe, Middle East, etc., where healthcare systems are improving diagnostic capabilities for cancer and expanding access to modern diagnostic tools.
Global Health Programs: International health initiatives focused on enhancing cancer detection and management in low-resource settings.